Canada has already committed to purchase 52 million doses of the vaccine and has executed its option for up to an additional 24 million doses.

NVX-CoV2373 is currently in phase III clinical development for the prevention of COVID-19. The company expects to supply NVX-CoV2373 to Canada beginning as early as the second quarter of 2021, following authorization by Canada's regulatory agency. Novavax also expects to announce initial phase III efficacy results as early as the first quarter of 2021.

New Zealand to purchase 10.7M doses of Novavax COVID-19 vaccine
The government of New Zealand has agreed to purchase 10.7 million doses of Novavax's COVID-19 vaccine candidate, NVX-CoV2373.

Novavax provides updates on COVID-19 vaccine
Novavax has reported that it is making "meaningful progress" on its COVID-19 vaccine, NVX‑CoV2373.

Endo to provide fill-finish services for Novavax COVID-19 vaccine
Par Sterile Products has entered a nonexclusive agreement with Novavax to provide fill-finish manufacturing services at its Rochester, MI, plant for Novavax's...

Novavax begins phase II trial of COVID-19 vaccine
Novavax has dosed the first participants in a phase II portion of an ongoing clinical trial to investigate the immunogenicity and safety of NVX-CoV2373,...